Clinical Trial Update: EBV CTLs Expressing CD30 Chimeric Receptors For CD 30+ Lymphoma [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating EBV-specific cytotoxic T lymphocytes engineered to express a CD30 chimeric receptor for CD30-positive Hodgkin lymphoma and CD30-posit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• EBV CTLs expressing CD30 chimeric receptor (EBV-specific cytotoxic T lymphocytes with CD30 CAR)

Snippet

Sponsor: Baylor College of Medicine | Conditions: Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING